Instituto Valenciano de Oncologia

Running trials

• Recruiting

  Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

  NCT06724159· Source

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Source

• Active, not recruiting

  Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

  NCT06225596· Phase 2· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Source

• Active, not recruiting

  Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

  NCT05024773· Phase 3· Source

• Recruiting

  Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

  NCT05673681· Source

• Recruiting

  First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  NCT05216432· Phase 1· Source

• Active, not recruiting

  Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

  NCT04994795· Source

• Active, not recruiting

  Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

  NCT03605771· Source

• Active, not recruiting

  A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

  NCT03473743· Phase 1/2· Source

• Recruiting

  International Registry for Men With Advanced Prostate Cancer (IRONMAN)

  NCT03151629· Source

• Recruiting

  Thoracic Tumours Register

  NCT02941458· Source

• Recruiting

  Spanish Urological Association Registry of Patients on Active Surveillance

  NCT02865330· Source

• Recruiting

  AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

  NCT02102165· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer3 recruiting
• Childhood cancers2 recruiting
• Prostate cancer2 recruiting
• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Source

• Completed

  Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)

  NCT04240106· Phase 2· Source

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Source

• Terminated

  Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

  NCT03753919· Phase 2· Source

• Completed

  Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

  NCT03556839· Phase 3· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Completed

  Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

  NCT02448420· Phase 2· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Source